These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 988964)

  • 21. Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias.
    Nademanee K; Feld G; Hendrickson J; Singh PN; Singh BN
    Circulation; 1985 Sep; 72(3):555-64. PubMed ID: 4017207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease.
    Kopelman HA; Woosley RL; Lee JT; Roden DM; Echt DS
    Am J Cardiol; 1988 May; 61(13):1006-11. PubMed ID: 3284316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of (+/-)-sotalol in healthy male volunteers.
    Kimura M; Umemura K; Ikeda Y; Kosuge K; Mizuno A; Nakanomyo H; Ohashi K; Nakashima M
    Br J Clin Pharmacol; 1996 Nov; 42(5):583-8. PubMed ID: 8951189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies on the pharmacokinetics and pharmacodynamics of the beta-adrenergic blocking agent sotalol in normal man.
    Schnelle K; Klein G; Schinz A
    J Clin Pharmacol; 1979; 19(8-9 Pt 2):516-22. PubMed ID: 489770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of sotalol on systemic hemodynamics and electrophysiology in patients with life-threatening ventricular tachyarrhythmias].
    Fu G; Shan J; Wille B
    Zhonghua Nei Ke Za Zhi; 1999 Jan; 38(1):30-2. PubMed ID: 11798623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol.
    Somberg JC; Preston RA; Ranade V; Molnar J
    Cardiology; 2010; 116(3):219-25. PubMed ID: 20693799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. d-sotalol reduces heart rate in vivo through a beta-adrenergic receptor-independent mechanism.
    Yasuda SU; Barbey JT; Funck-Brentano C; Wellstein A; Woosley RL
    Clin Pharmacol Ther; 1993 Apr; 53(4):436-42. PubMed ID: 8386603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol.
    Leahey WJ; Neill JD; Varma MP; Shanks RG
    Eur J Clin Pharmacol; 1980 Jun; 17(6):419-24. PubMed ID: 7398733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between pharmacokinetics and pharmacodynamics of the beta adrenergic blocking drug sotalol in dogs.
    Ishizaki T; Tawara K
    J Pharmacol Exp Ther; 1979 Nov; 211(2):331-7. PubMed ID: 501565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical pharmacology of adrenergic beta receptor blockade with sotalol (MJ 1999)].
    Schnelle K
    Adv Clin Pharmacol; 1978; 18():1-111. PubMed ID: 212935
    [No Abstract]   [Full Text] [Related]  

  • 31. Sotalol in the treatment of angina pectoris. A double-blind cross-over study.
    Kentala E; Pyörälä K; Frick MH
    Ann Clin Res; 1974 Oct; 6(5):253-7. PubMed ID: 4614692
    [No Abstract]   [Full Text] [Related]  

  • 32. Hemodynamic effects of intravenous and oral sotalol.
    Mahmarian JJ; Verani MS; Pratt CM
    Am J Cardiol; 1990 Jan; 65(2):28A-34A; discussion 35A-36A. PubMed ID: 2403732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Studies on the pharmacokinetics and effects of beta-adrenergic blocking agents, sotalol (author's transl)].
    Tawara K
    Hokkaido Igaku Zasshi; 1977 May; 52(3):245-59. PubMed ID: 914235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Electrophysiological effects of intravenous sotalol. Relation with plasma levels].
    Dumoulin P; Weissenburger J; Poirier JM; Rosensztajn L; Gallet B; Jaillon P; Têtard C; Cheymol G; Valty J
    Arch Mal Coeur Vaiss; 1985 Apr; 78(4):562-8. PubMed ID: 3923983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of intravenous sotalol on ventricular arrhythmias occurring during maximal exercise stress testing.
    Stroobandt R; Kesteloot H
    Arch Int Pharmacodyn Ther; 1983 Aug; 264(2):290-7. PubMed ID: 6639220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prazosin kinetics in essential hypertension.
    Chau NP; Flouvat BL; Le Roux E; Safar ME
    Clin Pharmacol Ther; 1980 Jul; 28(1):6-11. PubMed ID: 7389255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs.
    Kienzle MG; Martins JB; Wendt DJ; Constantin L; Hopson R; McCue ML
    Am J Cardiol; 1988 May; 61(13):1012-7. PubMed ID: 3129926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects on exercise tachycardia during forty-eight hours of a series of doses of atenolol, sotalol, and metoprolol.
    Harron DW; Balnave K; Kinney CD; Wilson R; Russell CJ; Shanks RG
    Clin Pharmacol Ther; 1981 Mar; 29(3):295-302. PubMed ID: 7471600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute prolongation of myocardial refractoriness by sotalol.
    Bennett DH
    Br Heart J; 1982 Jun; 47(6):521-6. PubMed ID: 7082500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Haemodynamics and myocardial function after sotalol.
    Hutton I; Lorimer AR; Hillis WS; McCall D; Reid JM; Lawrie TD
    Br Heart J; 1972 Aug; 34(8):787-90. PubMed ID: 5070109
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.